Sanofi Stock Price, News & Analysis (EPA:SAN)

€75.54 -0.43 (-0.57 %)
(As of 11/17/2017 10:41 AM ET)
Previous Close€76.06
Today's Range€75.27 - €76.20
52-Week Range€73.39 - €92.97
Volume1.27 million shs
Average Volume1.92 million shs
Market Capitalization$95.42 billion
P/E RatioN/A
Dividend Yield3.92%
BetaN/A

About Sanofi (EPA:SAN)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.


Industry, Sector and Symbol:
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: EPA:SAN
  • CUSIP: N/A
  • Web: en.sanofi.com
Dividend:
  • Dividend Yield: 3.9%
Profitability:
  • Trailing EPS: €3.61
  • Net Margins: 15.85%
Misc:
  • Outstanding Shares: 1,260,000,000
 
Frequently Asked Questions for Sanofi (EPA:SAN)

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

15 brokerages have issued 1-year price targets for Sanofi's shares. Their predictions range from €75.00 to €100.00. On average, they expect Sanofi's share price to reach €88.20 in the next year. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee (Age 63)

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately €75.54.

How big of a company is Sanofi?

Sanofi has a market capitalization of $95.42 billion.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


MarketBeat Community Rating for Sanofi (EPA SAN)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  446 (Vote Underperform)
Total Votes:  809
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Sanofi (EPA:SAN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: €88.20
Consensus Price Target History for Sanofi (EPA:SAN)
Price Target History for Sanofi (EPA:SAN)
Analysts' Ratings History for Sanofi (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetDetails
11/3/2017S&P GlobalSet Price TargetNeutral€83.00View Rating Details
11/3/2017The Goldman Sachs Group, Inc.Set Price TargetNeutral€82.00View Rating Details
11/2/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
11/2/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
10/26/2017Morgan StanleySet Price TargetBuy€92.00View Rating Details
10/18/2017Deutsche Bank AGSet Price TargetBuy€96.00View Rating Details
10/16/2017Jefferies Group LLCSet Price TargetNeutral€90.00View Rating Details
10/6/2017Citigroup Inc.Set Price TargetNeutral€88.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
9/7/2017Kepler Capital MarketsSet Price TargetBuy€90.00View Rating Details
7/31/2017Sanford C. BernsteinSet Price TargetNeutral€90.00View Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
5/8/2017Barclays PLCSet Price TargetSell€75.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
12/6/2016S&P Global Inc.Set Price TargetNeutral€80.00View Rating Details
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Sanofi (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sanofi (EPA:SAN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi (EPA SAN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sanofi (EPA:SAN)
Latest Headlines for Sanofi (EPA SAN)
Source:
DateHeadline
Inside Sanofi’s Valuation after Its 3Q17 EarningsInside Sanofi’s Valuation after Its 3Q17 Earnings
finance.yahoo.com - November 15 at 7:56 AM
This Sanofi Franchise Reported Double-Digit Growth in 3Q17This Sanofi Franchise Reported Double-Digit Growth in 3Q17
finance.yahoo.com - November 15 at 7:56 AM
Sanofi Wants To Make A Major Footprint In The Multiple Sclerosis ... - Seeking AlphaSanofi Wants To Make A Major Footprint In The Multiple Sclerosis ... - Seeking Alpha
seekingalpha.com - November 14 at 7:34 AM
Sanofi (SAN) Given Average Recommendation of "Hold" by BrokeragesSanofi (SAN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 12 at 10:20 AM
Japans Takeda Moves Forward with Dengue Vaccine After Promising Clinical Results - FortuneJapan's Takeda Moves Forward with Dengue Vaccine After Promising Clinical Results - Fortune
fortune.com - November 9 at 12:55 PM
Sanofi, Principia agree to develop multiple sclerosis drug candidateSanofi, Principia agree to develop multiple sclerosis drug candidate
finance.yahoo.com - November 9 at 12:55 PM
Sanofi strikes licence deal with Principia Biopharma on multiple sclerosisSanofi strikes licence deal with Principia Biopharma on multiple sclerosis
finance.yahoo.com - November 9 at 12:55 PM
Here's Why the Best Is Yet to Come for Novavax, Inc.Here's Why the Best Is Yet to Come for Novavax, Inc.
finance.yahoo.com - November 9 at 12:55 PM
Takeda takes on Sanofi with new global dengue vaccine dataTakeda takes on Sanofi with new global dengue vaccine data
finance.yahoo.com - November 7 at 9:49 AM
Sanofi SA (SAN) Given a €78.00 Price Target by HSBC Holdings plc AnalystsSanofi SA (SAN) Given a €78.00 Price Target by HSBC Holdings plc Analysts
www.americanbankingnews.com - November 6 at 12:58 AM
Goldman Sachs Group, Inc. (The) Reiterates €82.00 Price Target for Sanofi SA (SAN)Goldman Sachs Group, Inc. (The) Reiterates €82.00 Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - November 5 at 12:50 PM
Eroding Analytics Drop Sanofi (SNY) to Buy - Investorplace.comEroding Analytics Drop Sanofi (SNY) to Buy - Investorplace.com
investorplace.com - November 4 at 1:08 PM
Regeneron Gets Another ShotRegeneron Gets Another Shot
finance.yahoo.com - November 4 at 1:08 PM
Chart School: Using Regeneron's Five-Year Rally to Study SupportChart School: Using Regeneron's Five-Year Rally to Study Support
finance.yahoo.com - November 4 at 1:08 PM
Regeneron Pharmaceuticals Gains A Bull Ahead Of EarningsRegeneron Pharmaceuticals Gains A Bull Ahead Of Earnings
finance.yahoo.com - November 4 at 1:08 PM
Edited Transcript of SAN.PA earnings conference call or presentation 2-Nov-17 1:30pm GMTEdited Transcript of SAN.PA earnings conference call or presentation 2-Nov-17 1:30pm GMT
finance.yahoo.com - November 4 at 1:08 PM
S&P Global Reiterates "€83.00" Price Target for Sanofi SA (SAN)S&P Global Reiterates "€83.00" Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - November 3 at 12:10 PM
Sanofi SA (SAN) Given a €97.00 Price Target at Berenberg BankSanofi SA (SAN) Given a €97.00 Price Target at Berenberg Bank
www.americanbankingnews.com - November 2 at 6:22 AM
Sanofi SA (SAN) Stock Rating Reaffirmed by J P Morgan Chase & CoSanofi SA (SAN) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - November 2 at 6:22 AM
What Analysts Recommend for Sanofi in 3Q17What Analysts Recommend for Sanofi in 3Q17
finance.yahoo.com - November 1 at 8:30 PM
What Analysts Expect from Sanofi’s 3Q17 EarningsWhat Analysts Expect from Sanofi’s 3Q17 Earnings
finance.yahoo.com - November 1 at 3:29 PM
Why Sanofi’s Revenues Could Fall in 3Q17Why Sanofi’s Revenues Could Fall in 3Q17
finance.yahoo.com - November 1 at 3:29 PM
Sanofi turns to artificial intelligence to beat flu - Financial TimesSanofi turns to artificial intelligence to beat flu - Financial Times
www.ft.com - November 1 at 8:25 AM
[$$] Sanofi turns to artificial intelligence to beat flu[$$] Sanofi turns to artificial intelligence to beat flu
finance.yahoo.com - October 31 at 9:05 AM
Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent AsthmaSanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma
finance.yahoo.com - October 31 at 9:05 AM
High-Level Measures for Earnings Momentum Make Sanofi (SNY) a Strong Buy - Investorplace.comHigh-Level Measures for Earnings Momentum Make Sanofi (SNY) a Strong Buy - Investorplace.com
investorplace.com - October 28 at 1:57 AM
Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®
finance.yahoo.com - October 25 at 10:11 AM
Biogen beats profit estimates, but sales of Spinraza disappoint - NasdaqBiogen beats profit estimates, but sales of Spinraza disappoint - Nasdaq
www.nasdaq.com - October 24 at 9:37 AM
UBS AG Reiterates €82.00 Price Target for Sanofi SA (SAN)UBS AG Reiterates €82.00 Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - October 23 at 11:54 AM
Sanofi (SNY) a Strong Buy on Outstanding Quant Score - Investorplace.comSanofi (SNY) a Strong Buy on Outstanding Quant Score - Investorplace.com
www.investorplace.com - October 20 at 9:53 PM
Sanofi Stock: Performance in 3Q17Sanofi Stock: Performance in 3Q17
finance.yahoo.com - October 20 at 4:52 PM
Deutsche Bank AG Reiterates "€96.00" Price Target for Sanofi SA (SAN)Deutsche Bank AG Reiterates "€96.00" Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - October 18 at 10:59 AM
Sanofi SA (SAN) Receives Average Rating of "Hold" from BrokeragesSanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 18 at 10:30 AM
Regeneron-Sanofi throat infection drug succeeds key study - ReutersRegeneron-Sanofi throat infection drug succeeds key study - Reuters
www.reuters.com - October 17 at 3:35 PM
Regeneron-Sanofi Drug Succeeds Mid-Stage Study - New York TimesRegeneron-Sanofi Drug Succeeds Mid-Stage Study - New York Times
www.nytimes.com - October 17 at 3:35 PM
Regeneron-Sanofi drug succeeds mid-stage studyRegeneron-Sanofi drug succeeds mid-stage study
finance.yahoo.com - October 17 at 3:35 PM
Sanofi SA (SAN) PT Set at €82.00 by Goldman Sachs Group, Inc. (The)Sanofi SA (SAN) PT Set at €82.00 by Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 17 at 12:16 PM
Regeneron-Sanofi food allergy drug succeeds mid-stage study - ReutersRegeneron-Sanofi food allergy drug succeeds mid-stage study - Reuters
www.reuters.com - October 17 at 6:59 AM
UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage studyUPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
finance.yahoo.com - October 17 at 6:59 AM
Sanofi SA (SAN) Given a €90.00 Price Target at Jefferies Group LLCSanofi SA (SAN) Given a €90.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - October 16 at 9:44 AM
Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive ItBig Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It
finance.yahoo.com - October 14 at 7:33 AM
Sanofi and Its Peers: Analysts’ Recommendations in OctoberSanofi and Its Peers: Analysts’ Recommendations in October
finance.yahoo.com - October 14 at 7:33 AM
Specialty Segment Drives Sanofi’s Revenue Growth in 2017Specialty Segment Drives Sanofi’s Revenue Growth in 2017
finance.yahoo.com - October 14 at 7:33 AM
A Deep Dive Into MannKinds Big Bet On Afrezza - BenzingaA Deep Dive Into MannKind's Big Bet On Afrezza - Benzinga
www.benzinga.com - October 12 at 3:48 PM
Appeals court rules against Amgen in patent case - MarketWatchAppeals court rules against Amgen in patent case - MarketWatch
www.marketwatch.com - October 7 at 8:12 AM
Analytics Keep Sanofi (SNY) Strong Buy Ranking - Investorplace.comAnalytics Keep Sanofi (SNY) Strong Buy Ranking - Investorplace.com
investorplace.com - October 7 at 8:12 AM
Citigroup Inc. Analysts Give Sanofi SA (SAN) a €88.00 Price TargetCitigroup Inc. Analysts Give Sanofi SA (SAN) a €88.00 Price Target
www.americanbankingnews.com - October 6 at 12:28 PM
Morgan Stanley Reiterates €92.00 Price Target for Sanofi SA (SAN)Morgan Stanley Reiterates €92.00 Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - October 6 at 10:28 AM
US court reverses ban on sale of Regeneron, Sanofi cholesterol drug - ReutersUS court reverses ban on sale of Regeneron, Sanofi cholesterol drug - Reuters
www.reuters.com - October 6 at 8:32 AM
Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales WeakSanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak
finance.yahoo.com - October 3 at 12:04 PM

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.
This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.